AG¡¤×ðÁú¿­Ê± - ÈËÉú¾ÍÊDz«!

ÈÕ±¾ÕZ
ÐÂÎÅÖÐÐÄ

9/24

2024

ϲ±¨£¡º£ºÍÒ©ÎïMETÒÖÖƼÁº£Òæ̹® ¼´½«ÔÚÈÕ±¾ÉÌÒµÉÏÊÐ

º£ºÍÒ©Îï½ñÈÕÐû²¼£¬¹«Ë¾×ÔÖ÷¿ª·¢²¢ÓµÓÐÍêȫ֪ʶ²úȨµÄ´´ÐÂÒ©ÎïMETÒÖÖƼÁº£Òæ̹®50mgƬ¼Á£¨Í¨ÓÃÃû³Æ£º¹ÈÃÀÌæÄáƬ£¬ÈÕ±¾²úÆ·Ãû£º¥Ï¥¤¥¤©`¥¿¥ó®åV50©J£©½«ÓÚÖйúʱ¼ä2024Äê10ÔÂ11ÈÕÔÚÈÕ±¾ÉÌÒµÉÏÊС£

 

2024Äê6Ô£¬º£ºÍ×ÔÖ÷Ñз¢²¢ÓµÓÐÍêȫ֪ʶ²úȨµÄ´´ÐÂÒ©ÎïMETÒÖÖƼÁ¹ÈÃÀÌæÄáƬÒÑ»ñµÃÈÕ±¾ºñÉúÀͶ¯Ê¡Åú×¼ÉÏÊУ¬ÓÃÓÚÖÎÁÆЯ´øMETÍâÏÔ×Ó14ÌøԾͻ±äµÄ²»¿ÉÇгý¡¢ÍíÆÚ»ò¸´·¢µÄ·ÇСϸ°û·Î°©¡£ÈÕ±¾ÉÏÊвúÆ·ÐÅÏ¢£º50mg£¬24Ƭ/ºÐ¡£¶¨¼Û£º4,382.30ÈÕÔª/Ƭ¡£

 

2024Äê2Ôº£ºÍÒ©ÎïÓë´óÅôÒ©Æ·¹¤ÒµÖêʽ»áÉç´ï³É¹ÈÃÀÌæÄáƬ£¨SCC244£©ÔÚÈÕ±¾µÈµØÇøµÄ¶À¼ÒÐí¿ÉЭÒé¡£

 
º£ºÍÒ©ÎïÊ×ϯִÐйٶ­Èðƽ²©Ê¿±íʾ£º
“ÎÒÃǺܸßÐĵؿ´µ½£¬¹ÈÃÀÌæÄáƬÔÚÈÕ±¾»ñÅúÉÏÊк󲻾þÍʵÏÖÉÌÒµ»¯ÉÏÊУ¬Ï£ÍûÔÚº£ºÍÒ©Îï¼°ÆäºÏ×÷»ï°é——´óÅôÒ©Æ·¹²Í¬Å¬Á¦Ï£¬Èøü¶àÈ«ÇòؽÐèMETÒÖÖƼÁÖÎÁƵĻ¼ÕßÓÃÉϹÈÃÀÌæÄᣡ”
 
¹ØÓÚMETex14Ìø±äºÍNSCLC

Ô­·¢ÐԷΰ©ÊÇÖйú·¢²¡ÂʺÍËÀÍöÂÊ×î¸ßµÄ¶ñÐÔÖ×Áö£¬NSCLCÔ¼Õ¼ËùÓзΰ©µÄ85%1£¬METex14Ìø±äÔÚ·ÇСϸ°û·Î°©ÖеÄ×Ü·¢ÉúÂÊԼΪ3%2£¬ÔÚÖйúNSCLCÈËȺÖеķ¢ÉúÂÊÔ¼1.3%3¡£METex14Ìø±äÊÇÔ­·¢Ö°©Çý¶¯»ùÒò£¬METex14Ìø±äͨ³£²»ÓëEGFR¡¢ KRASºÍALKµÈ·Î°©ÆäËûÍ»±ä¹²´æ4 ¡£METex14Ìø±äԤʾԤºó²î£¬»¯ÁÆÒ©Îï¶þÏßÖÎÁÆÎÞ½øÕ¹Éú´æʱ¼ä£¨PFS£©½öΪ2.9¸öÔ£¬×ÜÉú´æÆÚ£¨OS£©Îª7.9-8.3¸öÔÂ5¡£ÃâÒßÖÎÁÆÓÃÓÚMETex14Ìø±ä»¼Õß»ñÒæÓÐÏÞ£¬ORRΪ16~17%£¬ÖÐλPFSΪ1.9~3.4¸öÔ 6,7¡£

¹ØÓÚ¹ÈÃÀÌæÄáƬ£¨Ñз¢´úºÅ£ºSCC244£©

¹ÈÃÀÌæÄáƬ£¨Ñз¢´úºÅ£ºSCC244£©ÊÇÒ»¿î¿Ú·þǿЧ¡¢¸ßÑ¡ÔñÐÔС·Ö×ÓMETÒÖÖƼÁ¡£ÁÙ´²Ç°Ñо¿ÏÔʾ¹ÈÃÀÌæÄáƬ¿ÉǿЧºÍÌØÒìÐÔ°ÐÏòÒÖÖÆMET¼¤Ã¸»îÐÔ¡£ÁÙ´²Ñо¿½á¹ûÏÔʾ£¬¹ÈÃÀÌæÄáƬ¾ßÓÐÓÅÁ¼µÄÒ©´ú¶¯Á¦Ñ§ÌØÐÔÒÔ¼°Á¼ºÃµÄ°²È«ÐÔºÍÄÍÊÜÐÔ£¬ÔÚ¾ßÓÐMET¸Ä±äµÄÍíÆÚ·ÇСϸ°û·Î°©»¼ÕßÖÐÏÔʾÁËÃ÷È·ÁÆЧÇÒÄÔתÒÆ»¼ÕßͬÑù»ñÒæ¡£ÓëÒÑÉÏÊÐͬÀà²úÆ·Ïà±È£¬¹ÈÃÀÌæÄáƬÎÈ̬¹ÈŨ¶È¸ü¸ß£¬¿ÉÒÔ³ÖÐøÒÖÖưеã; °ëË¥ÆÚ³¤£¬ÊʺÏÿÈÕÒ»´Î¸øÒ©; ²»ÐèÒª¸ù¾ÝÌåÖص÷Õû¼ÁÁ¿; Ò©ÎïÏ໥×÷ÓÃÉÙ£¬ºÏ²¢ÓÃÒ©°²È«ÐÔ·çÏյ͡£¹ÈÃÀÌæÄáƬ³É¹¦ÄÉÈëÍ»ÆÆÐÔÖÎÁÆÒ©Î²¢»ñµÃÖйúÒ©Æ·¼à¶½¹ÜÀí¾Ö£¨NMPA£©Åú×¼ÉÏÊÐÓÃÓÚMET 14ÍâÏÔ×ÓÌøԾͻ±äµÄ¾Ö²¿ÍíÆÚ»òתÒÆÐÔNSCLC»¼Õß¡£Í¬Ê±£¬Ò²ÕýÔÚ»ý¼«¿ªÕ¹ÆäËûÁÙ´²Ñо¿£¬±ÈÈçÕë¶ÔMET¹ý±í´ïÇÒÇý¶¯»ùÒòÒõÐÔµÄNSCLC»¼ÕßµÄIIIÆÚÁÙ´²Ñо¿¡£

¹ØÓÚº£ºÍÒ©Îï

º£ºÍÒ©ÎïÊÇÖйúÁìÏȵÄ×ÔÖ÷´´ÐÂÉúÎï¼¼Êõ¹«Ë¾£¬×¨×¢ÓÚ¿¹Ö×Áö´´ÐÂÒ©ÎïµÄ·¢ÏÖ¡¢¿ª·¢¡¢Éú²ú¼°ÉÌÒµ»¯£¬Ï£ÍûΪȫÇò°©Ö¢»¼Õß´øÀ´¸ü°²È«¡¢¸üÓÐЧµÄÖÎÁÆ·½·¨¡£º£ºÍÒ©Îï¼á³Ö×ß×ÔÖ÷´´ÐµĵÀ·£¬Í¬Ê±ÓµÓÐÒ»Ö§¾ßÓÐÈ«Çò»¯ÊÓÒ°µÄ¿ÆÑк͹ÜÀíÍŶÓ£¬»ý¼«²¼¾Ö´´ÐÂÒ©ÎïµÄ¹ú¼Ê¿ª·¢Ö®Â·¡£Ä¿Ç°º£ºÍÒ©ÎïÒÑÓÐ1¿î²úÆ·(¹ÈÃÀÌæÄáƬ£¬ÖÐÎÄÉÌÆ·Ãû£ºº£Òæ̹®£¬ÈÕ±¾ÉÌÆ·Ãû£º¥Ï¥¤¥¤©`¥¿¥ó®åV50©J£©ÔÚÖйúºÍÈÕ±¾¾ù»ñÅúÉÏÊУ¬²¢±»ÁÐÈëÖйú¡¶¹ú¼Ò»ù±¾Ò½ÁƱ£ÏÕ¡¢¹¤É˱£ÏÕºÍÉúÓý±£ÏÕҩƷĿ¼£¨2023Äê°æ£©¡·£¬ÒÔ¼°ÈÕ±¾Ò©¼Û»ù×¼ÊÕÔØƷĿĿ¼£¬ÁíÓжà¸öÔÚÑÐÖصã¹ÜÏߵĺòÑ¡Ò©Îï¡£

¹ØÓÚ´óÅôÒ©Æ·¹¤ÒµÖêʽ»áÉ磨ÈÕ±¾£©

´óÅôÒ©Æ·ÊÇ´óÚ£¿Ø¹ÉÖêʽ»áÉ磨https://www.otsuka.com/en/£©µÄ×Ó¹«Ë¾£¬ÆäÆóÒµÀíÄîÊÇ“ÎÒÃǽ«ÎªÌá¸ßÈËÃǵĽ¡¿µË®Æ½£¬¹¹Öþµ½´¦³äÂúЦÈݵÄÉç»á×÷³ö¹±Ï×”¡£´óÅôÒ©Æ·ÊÇÒ»¼ÒרעÓÚ°©Ö¢ÁìÓòºÍ¹ýÃô/ÃâÒßѧÁìÓòµÄ¡¢ÒÔÑз¢Îªµ¼ÏòµÄרҵÖÆÒ©¹«Ë¾¡£ÓÈÆäÔÚ°©Ö¢ÁìÓò£¬±»ÓþΪÈÕ±¾ÁìÏȹ«Ë¾Ö®Ò»£¬²¢ÕýÔÚ»ý¼«Íƶ¯È«Çò»¯¡£ÔÚ°©Ö¢ÒÔÍâµÄÁìÓòÒ²Ñз¢ºÍÏúÊÛÓÅÖʵIJúÆ·£¬ÕâЩ²úÆ·¿ÉÒÔÓÐЧÖÎÁÆÏà¹Ø¼²²¡²¢ÓÐÖúÓÚ¸ÄÉÆÈËÃǵÄÉú»îÖÊÁ¿¡£´ËÍ⣬ÖÂÁ¦ÓÚÌṩÏû·ÑÕß±£½¡²úÆ·£¬Ê¼ÖÕÒÔÏû·ÑÕß·ÅÔÚÊ×룬ÒÔ°ïÖúÈËÃǹýÉϳäʵ¶øÓÐÒâÒåµÄÉú»î¡£ÓйشóÅôÒ©Æ·µÄ¸ü¶àÐÅÏ¢£¬Çë·ÃÎÊ https://www.taiho.co.jp/en/¡£

²Î¿¼ÎÄÏ×£º

  1. [Sung, H., et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 2021. 71(3): p. 209-249.
  2. Cao, W., et al., Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl), 2021. 134(7): p. 783-791.
  3. Jemal, A., et al., Cancer Statistics, 2010. CA: A Cancer Journal for Clinicians, 2010. 60(5): p. 277-300.
  4. Vuong, H.G., et al., Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis. Lung Cancer, 2018. 123: p. 76-82. Lancet. 2009;374(9699):1432–1440.
  5. Ciuleanu T, Brodowicz T, Zielinski C, et al (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet, 374:1432-40.
  6. Ettinger DS, Akerley W, Bepler G, et al (2010), Non-small cell lung cancer. J Natl Compr Canc Netw, 8:740–801.
  7. Paz-Ares L, Luft A, Vicente D et al (2018), Pembrolizumab plus chemotherapy for squamous non-small cell lung cancer. N Engl J Med, 379:2040-51
| ·¨ÂÉÉùÃ÷ | ÃâÔðÉùÃ÷ | ÁªÏµÎÒÃÇ | Ò½Ò©´ú±í±¸°¸¹«Ê¾ |
¹Ø×¢ÎÒÃÇ
?2020 ÉϺ£º£ºÍÒ©ÎïÑо¿¿ª·¢¹É·ÝÓÐÏÞ¹«Ë¾
°æȨËùÓÐ »¦ICP±¸12016151ºÅ-1
¡¾ÍøÕ¾µØͼ¡¿¡¾sitemap¡¿
ÓÑÇéÁ´½Ó£ºZ6¡¤×ðÁú¿­Ê±¡¸Öйú¡¹¹Ù·½ÍøÕ¾  ÈËÉú¾ÍÊDz©¡¤ÖйúÇø¹Ù·½ÍøÕ¾  ×ðÁú¿­Ê±¡¸ÖйúÇø¡¹ÈËÉú¾ÍÊDz«!  ÈËÉú¾ÍÊDz©(ÖйúÇø)¹Ù·½ÍøÕ¾  ×ðÁú¿­Ê±ÈËÉú¾ÍÊDz«¡¤¡¸ÖйúÇø¡¹°Ù¶È°Ù¿Æ  ×ðÁú¿­Ê± - ÈËÉú¾ÍÊDz«!  Z6¡¤×ðÁú¿­Ê±¡¸Öйú¡¹¹Ù·½ÍøÕ¾  ÈËÉú¾ÍÊDz©¡¤(ÖйúÇø)¹Ù·½ÍøÕ¾